Abbreviated Curriculum Vitae



Eleftherios P. Diamandis

Revised April 28, 2017

Department of Pathology
and Laboratory Medicine
Mount Sinai Hospital
Suite Rm6-201
60 Murray Street
Toronto, Ontario, Canada M5T 3L9

Department of Clinical Biochemistry
University Health Network
200 Elizabeth Street
Toronto, Ontario, Canada M5G 2C4

Department of Laboratory Medicine
and Pathobiology
Faculty of Medicine
University of Toronto
1 King's College Circle, Rm 6231
Toronto, Ontario, Canada M5S 1A8

Contact Information

Mail Address: Box 32
60 Murray Street
Mount Sinai Hospital
Toronto, ON, Canada M5T 3L9

Telephone: 416-586-8443; Fax: 416-619-5521; Mobile: 416-505-2844

E-Mail: eleftherios.diamandis@sinaihealthsystem.ca

Web Site: http:/www.acdcLab.org/

Table of Contents

Date and Place of Birth

October 8, 1952 in Limassol, Cyprus

Elementary Education

Elementary and High School in Limassol, Cyprus. Graduation, June 1970

Citizenship Status

Citizen of Canada

Citizen of Cyprus

Degrees

1972-76	B.Sc.	Chemistry, University of Athens, Greece
1976-79	Ph.D.	Analytical Chemistry, University of Athens, Greece
1982-84	Clinical Biochemistry Diploma	University of Toronto, Canada
1978-82, 1984-86	M.D.	University of Athens, Greece

Present Positions

Division Head, Clinical Biochemistry, Department of Pathology and Laboratory Medicine
Mount Sinai Hospital, Toronto, Ontario, Canada [1995 to present]

Professor and Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology,
Faculty of Medicine, University of Toronto, Ontario, Canada [1997 to present]

Biochemist-in-Chief, Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada [2005 to present]

Hold'em for Life Chair in Prostate Cancer Biomarkers [2010 to present]

Cross-Appointments

Department of Surgery, Faculty of Medicine, University of Toronto [2006 to present]

Previous Positions

Dates	Position Held
1970-1972	Served in the Cyprus Army.
Aug 1976 - Jan 1978	Post-graduate student, Hellenic National Research Foundation.
Jan 1978 - Oct 1979	Research Assistant, Laboratory of Analytical Chemistry, University of Athens.
Nov 1979 - Aug 1982	Instructor, Laboratory of Analytical Chemistry, University of Athens.
Jul - Sep 1981	Post-Doctoral Research Associate, University of Illinois, Urbana-Champaign, USA.
Sep 1982 - Aug 1983	Trainee in Clinical Biochemistry, The Hospital for Sick Children, Toronto.
Sep 1983 - Mar 1984	Trainee in Clinical Biochemistry, Mount Sinai Hospital, Toronto.
Apr 1984 - Jul 1984	Trainee in Clinical Biochemistry, Sunnybrook Medical Centre, Toronto.
Aug 1985	Trainee in Pediatrics. Kaplan Hospital, Rehovot, Israel.
1982-1986	Lecturer, University of Athens.
1986-1988	Director of Research and Development, CyberFluor Inc. (Toronto).
1986-1990	Assistant Professor, Department of Clinical Biochemistry, University of Toronto.

Dates	Position Held
1988-1993	Chairman, Scientific Advisory Board, CyberFluor Inc.
1988-1994	Deputy Biochemist-in-Chief, Toronto Western Division, The Toronto Hospital.
Mar - Dec 1994	Director of Laboratories, Doctor's Hospital.
1990-1996	Associate Professor, Department of Clinical Biochemistry, University of Toronto.
1993-1997	Deputy Chair, Department of Clinical Biochemistry, University of Toronto.

Selected Distinctions and Awards

1. Chisholm Memorial Fellowship, Faculty of Medicine, University of Toronto (1983-84).
2. American Association for Clinical Chemistry Award for Outstanding Scientific Achievements by a Young Investigator (1985).
3. The MedChem Laboratories Award for the best poster presentation, at the annual Canadian Society of Clinical Chemists meeting. Co-author of nine winning posters in Vancouver (1985), Winnipeg (1988), Montreal (1991), Toronto (1992), Banff (1993), Quebec City (1994), Chicago (1996), Ottawa (1998), Chicago (2001).
4. Annual Van Slyke Society Research Grant Award of the American Association for Clinical Chemistry (1989).
5. Annual Research Excellence Award of the Canadian Society of Clinical Chemists (1995).
6. Excellence in Teaching Award, Department of Clinical Biochemistry, University of Toronto (1997).
7. Kubasik Lecturer, Upstate New York Section of the American Association for Clinical Chemistry (October 1998).
8. Distinguished Scientist Award, Clinical Ligand Assay Society (CLAS) (1999).
9. American Association for Clinical Chemistry Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research (1999).
10. Van Slyke Award, the New York Metro Section of the American Association for Clinical Chemistry (1999).
11. 1999 Burlina Prize. Co-author of best abstract presented at the International Society for Enzymology meeting in Venice, Italy, June 4-6, 1999.
12. Distinguished Scientist Award, National Academy of Clinical Biochemistry (NACB) (2000).
13. Honorary President, Society of Scientists / Clinical Chemists of Cyprus (April 2000).
14. Recognition of Scientific Contributions by the Municipality of Agios Athanasios, Limassol, Cyprus (2000).
15. Miriam Reiner Award from the Capital Section of the American Association for Clinical Chemistry (2001).
16. Abbott Award from the International Society for Oncodevelopmental Biology and Medicine (ISOBM) (2002).
17. Annual Education Excellence Award of the Canadian Society of Clinical Chemists (2003).
18. Elected "Corresponding Member" of the Academy of Athens (2005).
19. Frey-Werle Commemorative Gold Medal from the Frey-Werle Foundation (2007).
20. The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics from the American Association for Clinical Chemistry (AACC) (2007).
21. Outstanding Contributions to Clinical Biochemistry Award from the Ontario Society of Clinical Chemists (OSCC) (2008).
22. Elected "Member" of the Royal Society of Canada (2008).
23. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)/Abbott Award for Significant Contributions to Molecular Diagnostics (2009).
24. Distinguished Service Award, Department of Laboratory Medicine and Pathobiology, University of Toronto (2010).

25. Dr. Diamandis is highlighted for his citation record in: The Provincial Government of Ontario document entitled "Ontario's Innovation Agenda" (2010) [www.ontario.ca/innovation]; page 11.
26. Excellence in Biomedical Research Nemitsas Prize in Medical Sciences, Takis and Louki Nemitsas Foundation (2010).
27. Named "Hold'em for Life Chair in Prosate Cancer Biomarkers" (2010).
28. Elected Fellow of the American Association for the Advancement of Science (2011).
29. Elected Fellow of the Canadian Academy of Health Sciences (2012).
30. Senior Sustained Excellence in Graduate Teaching Award, Faculty of Medicine, University of Toronto (2013).
31. The Carl R. Joliff Award for Lifetime Achievement in Clinical and Diagnostic Immunology of AACC (2013).
32. Canadian Society of Clinical Chemists Award for Outstanding Contributions to Clinical Chemistry (2014).
33. The JJ Berry Smith Award for Excellence in Doctoral Supervision, University of Toronto, Canada (2014).
34. The Morton K. Schwartz Lectureship Award from the New York Metro Section of the American Association for Clinical Chemistry. (2014)
35. American Association for Clinical Chemistry Award for Outstanding Contributions in Education. (2017)

Certifications

1985	Certified Clinical Chemist by the Canadian Society of Clinical Chemists
1985	Certified Clinical Chemist by the American Board of Clinical Chemistry
1995	Fellow of the Royal College of Physicians, Canada
2006	Licensed Medical Biochemist, College of Physicians and Surgeons of Ontario, Canada [Registration # 85455]

Journal Referee

(selected list of 61)

1. Analytical Biochemistry
2. Analytical Chemistry
3. BMC Medicine
4. Brain
5. British Journal of Cancer
6. Cancer Epidemiology Biomarkers and Prevention
7. Cancer Research
8. Clinical Cancer Research
9. Clinical Chemistry
10. EMBO Journal
11. Genomics
12. International Journal of Cancer
13. Journal of Biological Chemistry
14. Journal of Neurochemistry
15. Journal of Urology
16. Journal of Clinical Oncology
17. Journal of Proteome Research
18. Journal of the National Cancer Institute
19. Lancet
20. Molecular and Cellular Proteomics
21. Nature Biotechnology
22. Nature Medicine
23. Oncogene
24. PLoS Medicine
25. Science

26. Science Translational Medicine

Member of Scientific Advisory / Editorial Boards

(selected list among 35 journals)

1. Member, Board of Editors, Clinical Chemistry (1995-2004) and Associate Editor (2008-)
2. Member, Editorial Board, British Journal of Cancer (2005-)
3. Member, Editorial Board, Cancer Letters (2005-2008)
4. Associate Editor, Cancer Research (2005-2008 and 2013-2015)
5. Member, Editorial Advisory Board, Molecular Oncology (2007-)
6. Member, Editorial Advisory Board, International Journal of Cancer (2008-)
7. Section Editor for Medical Biochemistry, Canadian Journal of Pathology (2009-2012)
8. Member, Editorial Board, BMC Medicine (2009-)
9. Member, Editorial Board, Clinical Chemistry & Laboratory Medicine (2011-)
10. Member, Editorial Board, Journal of Clinical Oncology (2012-2014)
11. Member, Editorial Board, Molecular Cancer Research (2013-2015)
12. Member, Editorial Board, Journal of Proteome Research (2011-)
13. Member, Editorial Board, Journal of Biological Chemistry (2013-2018)

Direction of PhD and MSc Theses

Completed PhD	: 32
Completed MSc	: 22
Post-Doctoral Fellows	: 40
Medical Residents	: 5
Research Assistants	: 18
Undergraduate/Co-Op Students	: 19
Summer Students & Volunteers	: 119
Committee Member of Graduate Students	: 31

Research Grants

(List includes only those with Dr.E.P. Diamandis as Principal Investigator; 1989 – 2017)

Granting Agency	Number of Awards	Total $
Canadian Institutes of Health Reasearch	11	2,690,532
Canadian Cancer Society Research Institute (formerly known as National Cancer Institute of Canada)	6	1,433,610
National Institutes of Health /EDRN	6	3,635,668
Natural Sciences and Engineering Research Council of Canada	11	5,595,000
Onatrio Institute for Cancer Research	8	2,128,528
Ontario Cancer Biomarker Network	1	6,000,000
Aventis Pasteur Vaccine Program	1	900,000
Other Agencies or Companies	21	2,828,000
Total	**65**	**25,211,338**

Invited Lectures

National and International Events : 182

Local and Commercial Events	: 39
Clinical Rounds	: 19
Roundtables	: 7
Interviews: Media Publications & Press Releases	: 100

List of Publications: Books

(selected from a list of 4)

1. *E.P. Diamandis*, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.)
   Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications (541 pages).
   AACC Press, Washington, DC, 2002.
2. *E.P. Diamandis*, T.K. Christopoulos. (Eds.)
   Immunoassay (579 pages). Academic Press, San Diego, CA 1996.

Book Chapters

Total Number: 42

Reviews

(selected from a list of 133 publications)

1. Prassas I, Eissa A, Poda G, *Diamandis EP*. Unleashing the therapeutic potential of human kallikrein-related serine peptidases. **Nat Rev Drug Discov** 2015;14:183-202
2. Muytjens CM, Vasiliou SK, Oikonomopoulou K, Prassas I, *Diamandis EP*. Putative functions of tissue kallikrein-related peptidases in vaginal fluid. **Nat Rev Urol.** 2016;13:596-607.
3. Drabovich AP, Saraon P, Jarvi k, *Diamandis EP*. Seminal plasma as a diagnostic fluid for male reproductive system disorders. **Nat Rev Urol** 2014;11:278-88.
4. Kulasingam V, Pavlou M, *Diamandis EP*. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. **Nat Rev Cancer** 2010;10:371-378.
5. Borgoňo CA, *Diamandis EP*. The emerging roles of human tissue kallikreins in cancer. **Nat Rev Cancer** 2004;4:876-890.
6. Kulasingam V, *Diamandis EP*. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. **Nat Clin Pract Oncol** 2008;5:588-599.
7. Prassas I, *Diamandis EP*. Novel therapeutic applications of cardiac glycosides. **Nat Rev Drug Discov** 2008;7:926-935.
8. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. **J Natl Cancer Inst**. 2015;107. doi: 10.1093/jnci/djv012.
9. Yousef GM, *Diamandis EP*. The new human tissue kallikrein gene family: Structure, function and association to disease. **Endocr Rev** 2001;22:184-204.
10. Lopez-Otin C, *Diamandis EP*. Breast and prostate cancer: An analysis of common epidemiological, genetic and biochemical features. **Endocr Rev** 1998;19:365-396.
11. Sotiropoulou G, Pampalakis G, *Diamandis EP*. Functional roles of human kallikrein-related peptidases. **J Biol Chem** 2009;284:32989-32994.
12. Farkona S, Diamandis EP, Blasutig I. Cancer immunotherapy: the beginning of the end of cancer? **BMC Med.** 2016;14:73

13. Dragani TA, Castells A, Kulasingam V, *Diamandis* EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology. **BMC Med**. 2016;14:110.

14. Kuzmanov U, Kosanam H, *Diamandis EP*. The sweet and sour of serological glycoprotein tumor biomarker quantification. **BMC Med** 2013;11:31.

15. Oikonomopoulou K, Brinc D, Kyriacou K, *Diamandis* EP. Infection and cancer: Revaluation of the hygience hypothesis. **Clin Cancer Res** 2013;19:2834-2841.

16. *Diamandis EP*. Fluorescence spectroscopy. **Anal Chem** 1993;65:454R-9R.

17. *Diamandis EP*, Christopoulos TK. Europium chelate labels in time-resolved fluorescence immunoassays and DNA hybridization assays. **Anal Chem** 1990;62;1149A-57A.

18. *Diamandis EP*, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family – implications in carcinogenesis. **Trends Endocrinol Metab** 2000;11:54-60.

19. *Diamandis EP*. Prostate specific antigen – its usefulness in clinical medicine. **Trends Endocrinol Metab** 1998;9:310-316.

20. Musrap N, *Diamandis EP*. Revisiting the complexity of the ovarian cancer microenvironment - clinical implicatons for treatment strategies. **Mol Cancer Res** 2012;10:1254-1264.

21. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, *Diamandis EP*. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. **Mol Cancer Res** 2012:10:1403-1418.

22. Borgoňo CA, Michael IP, *Diamandis EP*. Human tissue kallikreins: physiologic roles and applications in cancer. **Mol Cancer Res** 2004;2:257-280.

23. *Diamandis EP*. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. **Mol Cell Proteomics** 2004;3:367-378.

24. Kurlender L, Borgoňo C, Michael IP, Obiezu C, Elliott MB, Yousef GM, *Diamandis EP*. A survey of alternative transcripts of human tissue kallikrein genes. **Biochim Biophys Acta** 2005;1755:1-14.

25. Emami N, *Diamandis EP*. New insights into the functional mechanisms and clinical applicatons of the kallikrein-related peptidase family. **Mol Oncol** 2007;1:269-287.

26. Kulasingam V, *Diamandis EP*. Tissue culture-based breast cancer biomarker discovery platform. **Int J Cancer** 2008;123:2007-2012.

27. Musrap N, *Diamandis EP*. Prostate-specific antigen as a marker of hyperandrogenism in women and its implications for anti-doping. **Clin Chem** 2016;62:1066-74.

28. Duffy MJ, Sturgeon C, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt P. Validation of new cancer biomarkers: a position statement from the European Group on tumor markers. **Clin Chem** 2015; 61:809-820.

29. Chrystoja CC, *Diamandis EP*. Whole genome sequencing as a diagnostic test: challenges and opportunities. **Clin Chem**. 2014;60:724-33.

30. Bauça JM, Martínez-Morillo E, *Diamandis EP*. Peptidomics of urine and other biofluids for cancer diagnostics. **Clin Chem** 2014;60:1052-61.

31. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, *Diamandis EP*, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. **Clin Chem** 2013;59:52-9.

32. Pavlou M, *Diamandis EP*, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. **Clin Chem** 2013;59:147-157.

33. Rifai N, *Diamandis EP*, Lo YM, Kricka LJ, Wilding P, Ladenson JH, Wittwer CT. Advancing laboratory medicine through innovation: a tale of six inventors. **Clin Chem** 2012;58:502-510.

34. Konvalinka A, *Diamandis EP*. Searching for new biomarkers of renal diseases through proteomics. **Clin Chem** 2012;58:353-365.
35. Saraon P, Jarvi K, *Diamandis EP*. Molecular alterations during progression of prostate cancer to androgen independence. **Clin Chem** 2011;57:1366-1375.
36. Makawita S, *Diamandis EP*. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. **Clin Chem** 2010;56:212-222.
37. Sardana G, Dowell B, *Diamandis EP*. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. **Clin Chem** 2008;54:1951-1960.
38. Emami N, *Diamandis EP*. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. **Clin Chem** 2008;54:1600-1607.
39. Paliouras M, *Diamandis EP*. The kallikrein world: An update on the human tissue kallikreins. **Clin Chem** 2006;387;643-652.
40. *Diamandis EP*, Yousef GM. Human tissue kallikreins: A family of new cancer biomarkers. **Clin Chem** 2002;48:1198-1205.
41. *Diamandis EP*, Christopoulos TK. The biotin-(strept)avidin system: Principles and applications in biotechnology. **Clin Chem** 1991;37:625-36.
42. Chan A, *Diamandis EP*, Blasutig I. Strategies for discovering novel pancreatic cancer biomarkers. **J Proteomics** 2013;81:126-134.
43. Pavlou MP, Dimitromanolakis A, *Diamandis EP*. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. **J Proteomics** 2013;13:1083-1095.
44. Pavlou MP, *Diamandis EP*. The cancer cell secretome: A good source for discovering biomarkers? **J Proteomics** 2010;73:1896-1906**.**

Original Research Papers

(***selected from a list of 595 publications***)

1. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, Jarvi K, *Diamandis EP*. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. **Sci Transl Med.** 2013;5:212ra160.
2. Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek D.H, Fleshner N.E, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T,. Hunter G.A, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg M, Toi A, Shiah Y.J, Fraser M, van der Kwast T, Bristow R.G, Bapat B, *Diamandis E.P*, Boutros P.C,. Zlotta A.R. Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer. **J Natl Cancer Inst**.2017;109:1-11
3. Musrap N, Tuccitto A, Karagiannis GA, Saraon P, Batruch I, *Diamandis EP*. Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1). **J Biol Chem** 2015;290:17218-27.
4. Yu Y, Prassas I, Dimitromanolakis A, *Diamandis EP*. Novel Biological substrates of human kallikrein 7 identified through degradomics. **J Biol Chem** 2015;290:17762-75.
5. Konvalinka A, Zhou J, Dimitromanolakis A, Drabovich AP, Fang F, Gurley S, Coffman T, John R, Zhang SL, *Diamandis EP*, Scholey JW. Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC). **J Biol Chem** 2013;288:24834-47.
6. Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, *Diamandis EP*. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castrate-resistant prostate cancer. **J Biol Chem** 2012;287:34019-34031.

7. Eissa A, Amodeo V, Smith CR, *Diamandis EP*. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. **J Biol Chem** 2011;286:687-706.

8. Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuze-Vourc'h N, *Diamandis EP*, Courty Y. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. **J Biol Chem** 2011;286:25505-25518.

9. Emami N, Deperthes D, Malm J, Diamandis EP. Major role of human KLK14 in seminal clot liquefaction. **J Biol Chem** 2008;283:19561-9.

10. Emami N, *Diamandis EP*. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. **J Biol Chem** 2008;283:3031-41.

11. Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, *Diamandis EP*. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. **J Biol Chem** 2007;282:3640-52.

12. Borgoño CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, *Diamandis EP*. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. **J Biol Chem** 2007;282:2405-22.

13. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, *Diamandis EP*, Hollenberg MD. Proteinase-activated receptors, targets for kallikrein signaling. **J Biol Chem** 2006;281:32095-112.

14. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, *Diamandis EP*. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. **J Biol Chem** 2006;281:12743-50.

15. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, *Diamandis EP*. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. **J Biol Chem** 2005;280:14628-35.

16. Yousef GM, Scorilas A, Jung K, Ashworth LK, *Diamandis EP*. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. **J Biol Chem** 2001;276:53-61.

17. Yousef GM, Chang A, *Diamandis EP*. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. **J Biol Chem** 2000;275:11891-8.

18. Yousef GM, *Diamandis EP*. The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. **J Biol Chem** 1999;274:37511-6.

19. Yu H, *Diamandis EP*, Monne M, Croce CM. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. **J Biol Chem** 1995;270:6615-8.

20. Simon I, Zhuo S, Corral L, *Diamandis EP*, Sarno MJ, Wolfert RL, Kim NW. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. **Cancer Res** 2006;66:1570-5.

21. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, *Diamandis EP*. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. **Cancer Res** 2003;63:9032-41.

22. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, *Diamandis EP*. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. **Cancer Res** 2003;63:6543-6.

23. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgoño C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, *Diamandis EP*. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. **Cancer Res** 2003 Jul 15;63(14):3958-65. Erratum in: **Cancer Res** 2003;63:5647.

24. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, *Diamandis EP*. Human kallikrein 8, a novel biomarker for ovarian carcinoma. **Cancer Res** 2003;63:2771-4.

25. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, *Diamandis EP*. Parallel overexpression of seven kallikrein genes in ovarian cancer. **Cancer Res** 2003;63:2223-7.

26. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, *Diamandis EP*. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. **Cancer Res** 2003;63:807-11.

27. *Diamandis EP*, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. **Cancer Res** 2002;62:295-300.

28. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, *Diamandis EP*, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. **Cancer Res** 2001;61:7811-8.

29. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, *Diamandis EP*. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. **Cancer Res.** 2001;61:3425-31.

30. Yousef GM, Obiezu CV, Luo LY, Black MH, *Diamandis EP*. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. **Cancer Res** 1999;59:4252-6.

31. Yu H, Giai M, *Diamandis EP*, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. **Cancer Res** 1995;55:2104-10.

32. Yu H, *Diamandis EP*, Levesque M, Asa SL, Monne M, Croce CM. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. **Cancer Res** 1995;55:1603-6.

33. Monne M, Croce CM, Yu H, *Diamandis EP*. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. **Cancer Res** 1994;54:6344-7.

34. Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, *Diamandis EP*, Blasutig IM. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. **Clin Cancer Res** 2014;20:5787-95.

35. *Diamandis* EP, Goodglick L, Planque C, Thornquist M. Pentraxin-3 is a novel biomarker of lung carcinoma. **Clin Cancer Res** 2011;17:2395-2399.

36. Christensen E, Pintile M, Evans KR, Lenarduzzi M, Menard C, Catton CN, *Diamandis EP*, Bristow RG. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. **Clin Cancer Res** 2009;15:5576-5583.

37. Prassas I, Paliouras M, Datti A, *Diamandis EP*. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies. **Clin Cancer Res** 2008;14:5778-84.

38. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, *Diamandis EP*, Goodglick L. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. **Clin Cancer Res** 2008;14:1355-62.

39. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, *Diamandis EP*. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. **Clin Cancer Res** 2007;13:6984-92.

40. McIntosh MW, Liu Y, Drescher C, Urban N, *Diamandis EP*. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. **Clin Cancer Res** 2007;13:4422-8.

41. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, *Diamandis EP*, Harbeck N. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. **Clin Cancer Res** 2007;13:1742-8.

42. Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. **Clin Cancer Res** 2006;12:1487-93.

43. Luo LY, Shan SJ, Elliott MB, Soosaipillai A, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. **Clin Cancer Res** 2006;12:742-50.

44. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, *Diamandis EP*, Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. **Clin Cancer Res** 2006;12:89-96.

45. Santin AD, *Diamandis EP*, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. **Clin Cancer Res** 2005;11:3320-5.

46. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, *Diamandis EP*. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. **Clin Cancer Res** 2001;7:2372-9.

47. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, *Diamandis EP*. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. **Clin Cancer Res** 2001;7:2380-6.

48. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, *Diamandis EP*. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. **Clin Cancer Res** 2001;7:806-11.

49. Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, *Diamandis EP*. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. **Clin Cancer Res** 2000;6:3260-70.

50. Black MH, Giai M, Ponzone R, Sismondi P, Yu H, *Diamandis EP*. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. **Clin Cancer Res** 2000;6:467-73.

51. Scorilas A, *Diamandis EP*, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: An independent favorable prognostic factor in node-positive patients. **Clin Cancer Res** 1999;5:1778-85.

52. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. **Clin Cancer Res** 1998;4:1489-97.

53. Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, *Diamandis EP*. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signalling networks. **Mol Cancer Therapeutics** 2011;10:2083-2093.

54. Clotet S, Soler MJ, Riera M, Pascual J, Fang F, Zhou J, Batruch I, Vasiliou SK, Dimitromanolakis A, Barrios C, *Diamandis EP*, Scholey J, Konvalinka A. Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male SexHormones and Impaired Energy Metabolism in Diabetic Kidney Disease. **Mol Cell Proteomics.** 2017;16:368-385.

55. Drabovich AP, Pavlou MP, Schiza C, *Diamandis EP*. Dynamics of protein expression reveals primary targets and secondary messengers of estrogen receptor alpha signaling in mcf-7 breast cancer cells. **Mol Cell Proteomics**. 2016;15:2093-107.

56. Karakosta TD, Soosaipillai A, *Diamandis EP*, Batruch I, Drabovich AP. Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multi-Platform Targeted Mass Spectrometry Assays. **Mol Cell Proteomics.** 2016;15:2863-76

57. Drabovich AP, Pavlou MP, Schiza C, *Diamandis EP*. Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells. **Mol Cell Proteomics.** 2016;15:2093-107.

58. Korbakis D, Brinc D, Schiza C, Soosaipillai A, Jarvi K, Drabovich AP, *Diamandis EP*. Immunocapture-selected reaction monitoring screening facilitates the development of ELISA for the measurement of native TEX101 in biological fluids. **Mol Cell Proteomics** 2015;14:1517-26.

59. Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, *Diamandis EP*. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. **Mol Cell Proteomics** 2013;12:1589-601.

60. Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, *Diamandis EP*. LAMC2: A promising new pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. **Mol Cell Proteomics** 2013;12:2820-2832.

61. Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey CM, Jarvi K, *Diamandis EP*. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. **Mol Cell Proteomics** 2013;12:1589-1601.

62. Drabovich AP, Pavlou MP, Dimitromanolakis A, *Diamandis EP*. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. **Mol Cell Proteomics** 2012;11:422-434.

63. Makawita S, Smith C, Batruch I, Zheng Y, Reuckert F, Grutzmann R, Pilarsky C, Gallinger S, *Diamandis EP*. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. **Mol Cell Proteomics** 2011;10:M111.008599.

64. Drabovich AP, Jarvi K, *Diamandis EP*. Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monotiring assay. **Mol Cell Proteomics** 2011;10:M110-.004127.

65. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, *Diamandis EP*. Differential n-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. **Mol Cell Proteomics** 2009;8:791-798.

66. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, *Diamandis EP*. Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. **Mol Cell Proteomics** 2009;8:2746-2758.

67. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, *Diamandis EP*. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. **Mol Cell Proteomics** 2009;8:661-669.

68. Kulasingam V, *Diamandis EP*. Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. **Mol Cell Proteomics** 2007;6:1997-2011.

69. Cho CK, Shan SJ, Winsor EJ, *Diamandis EP*. Proteomics analysis of human amniotic fluid. **Mol Cell Proteomics** 2007;6:1406-1415.

70. Pavlou MP, Dimitromanolakis A, Martinez-Morillo E, Smid M, John A. Foekens JA, *Diamandis EP*. Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: Application in breast cancer. **J Proteome Res** 2014;13:2897-909.

71. Martínez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, Lopez MF, Minthon L, Bu G, Mattsson N, Portelius E, Hansson O, *Diamandis EP*. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. **J Proteome Res** 2014;13:1077-87.

72. Martinez-Morillo E, Hernández PG, Begcevic I, Kosanam H, Garcia BP, Alvarez-Menéndez FV, *Diamandis EP*. Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. **J Proteome Res** 2014;13:969-81.

73. Martinez-Morillo E, Cho C-K, Drabovich A, Shaw J, Soosaipillai A, *Diamandis EP*. Development of a multiplex selected reaction monitorig assay for quantification of biochemical markers of Down Syndrome in amniotic fluid samples. **J Proteome Res** 2012;11:3880-3887.

74. Prakash A, Rezai T, Krastins B, Sarracinol D, Athanas M, Russo P, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Oran LP, Fredolini C, Luchini A, Liotta L, Petricoin E, *Diamandis EP*, Chan DW, Nelson RW, Lopez MF. Inter laboratory reproducibility of SRM assays using multiple upfront analyte enrichment strategies. **J Proteome Res** 2012;11:3986-3995.

75. Batruch I, Smith CR, Mullen BJ, Grober E, Lo KC, *Diamandis EP*, Jarvi KA. Analysis of seminal plasma from patients with non-obstructive azoospermia and identification of candidate biomarkers of male infertility. **J Proteome Res** 2012;11:1503-1511.

76. Batruch I, Lecker I, Kagedan D, Smith C, Mullern B, Grober E, Kirk L, *Diamandis EP*, Jarvi K. Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. **J Proteome Res** 2011;10:941-953.

77. Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Ross MM, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Liotta L, Petricioin E, *Diamandis EP*, Chan DW, Lopez MF. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. **J Proteome Res** 2010;9:6678-6688.

78. Cho C-K, SmithCR, *Diamandis EP*. Amniotic fluid proteome analysis from Down Syndrome pregnancies for biomarker discovery. **J Proteome Res** 2010;9:3574-3582.

79. Drabovich A, *Diamandis EP*. Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. **J Proteome Res** 2010;9:1236-1245.

80. Gunawardana G, Kuk C, Smith CR, Batruch I, Soosaipillai A, *Diamandis EP*. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. **J Proteome Res** 2009;8:4705-4713.

81. Sardana G, Jung K, Stepham C, *Diamandis EP*. Proteomic analysis of conditioned media from PC3, LNCaP and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. **J Proteome Res** 2008;7:3329-3338.

82. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, *Diamandis EP*. "Product Ion Monitoring" assay for for prostate-specific antigen in serum using a linear Ion-trap. **J Proteome Res** 2008;7:640-647.

83. Shaw JL, Smith CR, *Diamandis EP*. Proteomic analysis of human cervico-vaginal fluid. **J Proteome Res** 2007;6:2859-2865.

84. Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, Klotz L, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, *Diamandis EP*, Yu C, Loblaw DA, Naron SA. Prospective multi-insitutional study evaluating the performance of prostate cancer risk calculators. **J Clin Oncol** 2011;29:2959-2964**.**

85. Scorilas A, Borgoño CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 13 protein in ovarian cancer cytosols: A new favorable prognostic marker. **J Clin Oncol** 2004;22:678-85.

86. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M, *Diamandis EP*. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. **J Clin Oncol** 2003;21:3119-26.

87. Nam RK, Zhang WW, Trachtenberg J, *Diamandis EP*, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, Narod SA. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. **J Clin Oncol** 2003;21:2312-9.

88. *Diamandis EP*, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. **J Clin Oncol** 2003;21:1035-43.

89. Sauter ER, *Diamandis EP*. Prostate-specific antigen levels in nipple aspirate fluid. **J Clin Oncol** 2001;19:3160.

90. Nam RK, *Diamandis EP*, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. **J Clin Oncol** 2000;18:1036-42.

91. Levesque MA, Yu H, Clark GM, *Diamandis EP*. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. **J Clin Oncol** 1998;16:2641-50.

92. Elliott MB, Irwin DM, *Diamandis EP*. In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. **Genomics** 2006;88:591-9.

93. Jung K, *Diamandis EP*. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. **Genomics** 2001;74:385-95.

94. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, *Diamandis EP*. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. **Genomics** 2001;72:217-21.

95. Yousef GM, Magklara A, *Diamandis EP*. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. **Genomics** 2000;69:331-41.

96. Foussias G, Yousef GM, *Diamandis EP*. Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). **Genomics** 2000;67:171-8.

97. Yousef GM, *Diamandis EP*. The expanded human kallikrein gene family: Locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). **Genomics** 2000;65:184-94.

98. Yousef GM, Scorilas A, *Diamandis EP*. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. **Genomics** 2000;63:88-96.

99. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, *Diamandis EP*. Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. **Genomics** 1999;62:251-9.

100. Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, *Diamandis EP*. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. **J Clin Endocrinol Metab** 2001;86:1558-61.

101. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, *Diamandis EP*. Prostate-specific antigen in female serum, a potential new marker of androgen excess. **J Clin Endocrinol Metab** 1997;82:777-80.

102. Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, *Diamandis EP*. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. **J Invest Dermatol** 2008;128:1148-59.

103. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Wu HK, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol** 2006;126:2338-42.

104. Komatsu N, Tsai B, Sidiropoulos M, Saijoh K, Levesque MA, Takehara K, *Diamandis EP*. Quantification of eight tissue kallikreins in the stratum corneum and sweat. **J Invest Dermatol** 2006;126:925-9.

105. Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, Takehara K, *Diamandis EP*. Quantification of human tissue kallikreins in the stratum corneum: Dependence on age and gender. **J Invest Dermatol** 2005;125:1182-9.

106. Rabien A, Fritzsche F, Jung M, Tolle A, *Diamandis EP*, Miller K, Jung K, Kristiansen G, Stephan C. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. **Int J Cancer** 2010;127:2386-2394.

107. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, *Diamandis EP*. Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. **Int J Cancer** 2009;125:9-14.

108. Sauter ER, Lininger J, Magklara A, Hewett JE, *Diamandis EP*. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. **Int J Cancer** 2004;108:588-91.

109. Borgoño CA, Fracchioli S, Yousef GM, Rigault de la Longrais IA, Luo LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, *Diamandis EP*, Katsaros D. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. **Int J Cancer** 2003;106:605-10.

110. Sauter ER, Welch T, Magklara A, Klein G, *Diamandis EP*. Ethnic variation in kallikrein expression in nipple aspirate fluid. **Int J Cancer** 2002;100:678-82.

111. Magklara A, Brown TJ, *Diamandis EP*. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. **Int J Cancer** 2002;100:507-14.

112. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Insulin-like growth factor-binding protein-3 and breast cancer survival. **Int J Cancer** 1998;79:624-8.

113. Levesque MA, D'Costa M, Spratt EH, Yaman MM, *Diamandis EP*. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. **Int J Cancer** 1998;79:494-501.

114. Levesque MA, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, *Diamandis EP*. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. **Int J Cancer** 1998;79:147-52.

115. Angelopoulou K, Stratis M, *Diamandis EP*. Humoral immune response against p53 protein in patients with colorectal carcinoma. **Int J Cancer** 1997;70:46-51.

116. Angelopoulou K, *Diamandis EP*, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. **Int J Cancer** 1994;58:480-7.

117. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, *Diamandis EP*. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. **Cancer** 1996;78:2146-52.

118. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, *Diamandis EP*. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. **Cancer** 1995;75:1327-38.

119. Goldberg DM, Tsang E, Karumanchiri A, *Diamandis EP*, Soleas G, Ng E. Method to assay the concentrations of phenolic constituents of biological interest in wines. **Anal Chem** 1996;68:1688-94.

120. Chan A, *Diamandis EP*, Krajden M. Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. **Anal Chem** 1993;65:158-63.

121. Christopoulos TK, *Diamandis EP*. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. **Anal Chem** 1992;64:342-6.

122. Christopoulos TK, *Diamandis EP*. Binding studies using ion-selective electrodes. Examination of the picrate-albumin interaction as a model system. **Anal Chem** 1990;62:360-7.

123. *Diamandis EP*, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. **Anal Chem** 1989;61:48-53.

124. Reichstein E, Shami Y, Ramjeesingh M, *Diamandis EP*. Laser-excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid as label. **Anal Chem** 1988;60:1069-74.

125. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, *Diamandis EP*, Hudson TJ, White JH. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. **Mol Endocrinol** 2002;16:1243-56.

126. Ban K, Kim KH, Cho CK, Sauve M, *Diamandis EP*, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1 (9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. **Endocrinology** 2010;151:1520-1531.

127. Yu H, *Diamandis EP*, Hoffman B. Elevated estradiol and testosterone levels and risk for breast cancer. **Ann Intern Med** 1999;131:715.

128. Hassapoglidou S, *Diamandis EP*, Sutherland DJ. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. **Oncogene** 1993;8:1501-9.

129. Christopoulos TK, *Diamandis EP*, Wilson G. Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. **Nucleic Acids Res** 1991;19:6015-9.

130. Cramer DW, Bast RC Jr, Berg CD, *Diamandis EP*, Goodwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal and ovarian cancer screening trial specimens. **Cancer Prev Res** (Phila) 2011;4:365-374.

131. Prassas I, Chrystoja CC, Makawita S, *Diamandis EP*. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. **BMC Med** 2012;10:39.

132. Korbakis D, Schiza C, Brinc D, Soosaipillai A, Karakosta TD, Légaré C, Sullivan R, Mullen B, Jarvi K, Diamandis EP, Drabovich AP. Preclinical evaluation of TEX101 protein ELISA test for the differential diagnosis of male infertility. **BMC Medicine.** 2017 [Epub ahead of print]

Editorials/Commentaries

(selected from a list of 73 publications)

1. *Diamandis EP*. The question I hate the most. **Nature** 2016;350:11
2. *Diamandis EP*. Time to reflect. **Nature** 2013;496:129.
3. Pavlou M, *Diamandis EP*. The athletes of science. **Nature** 2011:478: 419.
4. *Diamandis EP*. Getting noticed is half the battle. **Science**. 2015;349:206.
5. *Diamandis EP*. Perspective: Audacity is overrated. **Science** 2010 [online only]. [http://sciencecareers.sciencemag.org/career_magazine/previous_issues.articles/2009_11_06/caredit.a0900139].
6. *Diamandis EP*. Cancer biomarkers: can we turn recent failures into success? **J Natl Cancer Inst** 2010;102:1462-1467.
7. *Diamandis EP*. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. **J Natl Cancer Inst** 2004;96:353-356.
8. *Diamandis EP*. A day in the life of Dr. Bean-and how NIH is wasting $20 Billion per year. **Clin Chem** 2015;61:783-4.
9. *Diamandis EP*. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: Next steps. **Cancer Res** 2006;66:5540-1.
10. *Diamandis EP*. Lost in (the Business of) Translation: Invest in the Youth. **Clin Cancer Res** 2006;12:669.
11. *Diamandis EP*, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: Opportunities and limitations. **Clin Cancer Res** 2005;11:963-965.
12. Kulasingam V, Diamandis EP. Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics? **BMC Med.** 2016;14:186
13. Dragani TA, Castells A, Kulasingam V, *Diamandis EP*, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology. **BMC Med.** 2016;14:110.
14. *Diamandis EP*. The hundred person wellness project and Google's baseline study: Medical revolution or unnecessary and potentially harmful over-testing? **BMC Med** 2015;13:5.
15. *Diamandis EP*. Towards identification of true cancer biomarkers. **BMC Med** 2014;12:156.
16. Kulasingam V, *Diamandis EP*. Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. **BMC Med** 2013;11:53.
17. Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem? **BMC Med** 2012;10:87.
18. *Diamandis EP*. Peptidomics for cancer diagnosis: Present and future. **J Proteome Res** 2006;5:2079-2082.
19. *Diamandis EP*, Yu H. New biological functions of prostate-specific antigen? **J Clin Endocrinol Metab** 1995;80:1515-7.
20. Kulasingam V, *Diamandis EP*. Genomic profiling for copy number changes in plasma of ovarian cancer patients – new era for cancer diagnostics? **BMC Med** 2016
21. *Diamandis EP*. The journal impact factor is under attach – use CAPCI factor instead. **BMC Med.** 2017;15:9

Letters to the Editor

(selected from a list of 42 publications)

1. *Diamandis EP*. Publishing costs: Peer review as a business transaction. **Nature** 2015;517:145.
2. *Diamandis EP*. Support staff: Build reward system for ace technicians. **Nature** 2015;519:414.
3. *Diamandis EP*. OvaCheck: Doubts voiced soon after publication. **Nature** 2004;430:611.
4. *Diamandis EP*. The time of young scientists. **Science** 2010;329:626.

5. *Diamandis EP*. Proteomic patterns in serum and identification of ovarian cancer. **Lancet** 2002;360:170-171.
6. *Diamandis EP*, Yu H. Prostate specific antigen and lack of specificity for prostate cells. **Lancet** 1995;345:1186.
7. *Diamandis EP*. Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. **New Engl J Med** 2000;343:890-891.
8. *Diamandis EP*. BRCA1 protein products: Antibody specificity, functional motifs and secreted tumour suppressors. **Nature Genet** 1996;13:268.
9. *Diamandis EP*, Kulasingam V, Sardana G. Differential exoprotease activities confer tumor-specific serum peptidome. **J Clin Invest** 2006 [http://www.jci.org/cgi/eletters/116/1/271].
10. *Diamandis EP*. Serum proteomic patterns for detection of prostate cancer. **J Natl Cancer Inst** 2003;95:489-490.
11. Zaviacic C, Ablin RJ, • Response, *Diamandis EP*. The Female Prostate. **J Natl Cancer Inst** 1998;90:713-714.
12. Borchert GH, Giai M, *Diamandis EP*. Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. **J Natl Cancer Inst** 1997;89:587-588.
13. *Diamandis EP*. Clinical application of ultrasensitive prostate specific antigen assays. **J Natl Cancer Inst** 1997;89:1077.
14. Sauter ER, *Diamandis EP*. Prostate-specific antigen levels in nipple aspirate fluid. **J Clin Oncol** 2001;19:3160.
15. *Diamandis EP*. **Re:** Diagnostic potential of serum proteomic patterns in prostate cancer. **J Urol** 2004;171:1244-1245.
16. *Diamandis EP*. Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal cancinoma. **Clin Cancer Res** 2004;10:5293-5294.
17. *Diamandis EP*. Biomarker validation is still the bottleneck in biomarker research. **J Intern Med** 2012; 272:620.
18. *Diamandis EP*. A word of caution on new and revolutionary diagnostic tests (Letter commenting on the paper by Myron G. Best et al in Cancer Cell, 2015;28:666-76). **Cancer Cell** 2016; 29:141-142

Science Fiction

1. *Diamandis EP*. How to win Wimbledon championships: Creating Beklof and Vamos. **Clin Chem** 2009;55:1253-1254.
2. *Diamandis EP*. A conversation with Pheidias and Pericles about the Elgin Marbles and other matters. **Clin Chem** 2010;56:1042-1044.
3. *Diamandis EP*. Playing the trumpet. **Clin Chem** 2011;57:1789.

Patents

Patents Awarded	: 28
Patents Pending	: 26
Genbank Submissions	: 153

Abstracts

Abstracts in total	: 574

Author *h*-Index -as of December 19, 2016 – [data from "Publish or Perish Software; Google Scholar]

Eleftherios P. Diamandis Citations: *h*-Index
Total of *45,319* citations

***h*-Index** = *10*

International Lab Rankings –[2012]

According to various parameters, including citations, The ACDC Lab was ranked # 30 in the world (1st in Canada) among proteomics laboratories. Please visit the link: http://www.proteomicsresearch.org/labs.php

The ACDC Laboratory was ranked #5 in the world (1st in Canada) among protease laboratories. Please visit the link: http://www.proteases.org/labs.php